99mTc标记的S-HYNIC聚乙二醇化赛妥珠单抗在类风湿关节炎和脊柱关节炎患者中的生物分布与剂量学研究
本研究建立了靶向肿瘤坏死因子(TNF)的聚乙二醇化赛妥珠单抗(CZP)的99mTc标记方法,体外证实标记后TNF中和活性与未标记CZP相当,并在8例类风湿关节炎或脊柱关节炎患者中完成生物分布与剂量学评估。肾脏、脾脏和肝脏平均吸收剂量最高,分别为56(SD 7)、34(SD 6)和33(SD 7)μGy/MBq,有效剂量为6.1(SD 0.9)mSv。显像显示临床受累外周关节有明显示踪剂摄取,肿胀关节摄取比高于临床阴性关节。
要点
- 99mTc-S-HYNIC CZP体外TNF细胞毒中和活性与未标记CZP(含或不含HYNIC连接子)相当。
- 8例患者中肾脏、脾脏、肝脏平均吸收剂量分别为56(SD 7)、34(SD 6)、33(SD 7)μGy/MBq,有效剂量6.1(SD 0.9)mSv。
- 肿胀关节摄取比(中位数,类风湿关节炎3.3、外周脊柱关节炎2.4)高于临床阴性关节(分别为1.3和1.6)。
核心结论
- 研究建立了靶向TNF的Fab'片段药物CZP的放射性标记技术,估算有效剂量为6.1(SD 0.9)mSv,并证实该新放射性药物在临床受累外周关节中有摄取。
研究设计与样本
- 放射性标记与体外TNF中和活性试验,以及8例类风湿关节炎或脊柱关节炎患者的生物分布与剂量学研究。
- 全身显像及血液、尿液采样至注射后24小时,累积活度用单指数拟合估算,器官剂量用OLINDA/EXM估算,有效剂量按国际放射防护委员会103号建议计算。
- 外周关节示踪剂摄取采用视觉和半定量评估。
主要发现
- 体外试验显示99mTc-S-HYNIC CZP制剂可阻断TNF细胞毒性,效果与未标记CZP(含或不含HYNIC连接子)相当。
- 肾脏、脾脏、肝脏平均吸收剂量最高,分别为56(SD 7)、34(SD 6)、33(SD 7)μGy/MBq。
- 平均注射活度为690(SD 35)MBq时,有效剂量为6.1(SD 0.9)mSv;22.5小时尿排泄为注射活度的15.1%(SD 8.1)。
- 血液分析分布半衰期为1.2小时(SD 1.5),消除半衰期为26.9小时(SD 2.7)。
- 肿胀关节示踪剂摄取中位比值在类风湿关节炎为3.3、外周脊柱关节炎为2.4,高于临床阴性关节的1.3和1.6。
关键数值与推荐
- 肾脏平均吸收剂量56(SD 7)μGy/MBq,脾脏34(SD 6)μGy/MBq,肝脏33(SD 7)μGy/MBq。
- 平均注射活度690(SD 35)MBq时有效剂量6.1(SD 0.9)mSv。
- 22.5小时尿排泄为注射活度的15.1%(SD 8.1)。
- 分布半衰期1.2小时(SD 1.5),消除半衰期26.9小时(SD 2.7)。
- 肿胀关节中位摄取比:类风湿关节炎3.3、外周脊柱关节炎2.4;临床阴性关节分别为1.3和1.6。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for certolizumab pegol (CZP), a commercially available humanized Fab'-fragment directed against TNF. A biodistribution and dosimetry study was conducted. Tc-S-HYNIC CZP was synthesized. The in vitro TNF neutralizing activity was tested by exposing L929s-cells to various concentrations 99mTc-S-HYNIC CZP and measuring TNF-induced cytotoxicity. For biodistribution and dosimetry, WB images and blood and urine sampling were performed up to 24 h pi. Cumulative activities were estimated using mono-exponential fitting, and organ doses were estimated using OLINDA/EXM. The effective dose was calculated using the International Commission on Radiological Protection 103 recommendations. The uptake of the tracer in the peripheral joints was assessed visually and semiquantitatively. RESULTS: In vitro tests showed blocking of TNF cytotoxicity by the 99mTc-S-HYNIC CZP formulation comparable to the effect obtained with the unlabelled CZP with or without the HYNIC linker. We analysed eight patients with rheumatoid arthritis or spondyloarthritis. The highest mean absorbed organ doses were recorded for kidneys, spleen, and liver: 56 (SD 7), 34 (SD 6), and 33 (SD 7) μGy/MBq. The effective dose was 6.1 (SD 0.9) mSv for a mean injected activity of 690 (SD 35) MBq. The urinary excretion was 15.1% (SD 8.1) of the IA at 22.5 h. Blood analysis yielded a distribution half-life of 1.2 h (SD 1.5) and an elimination half-life of 26.9 h (SD 2.7). Visual analysis of the scans revealed marked tracer accumulation in the clinically affected peripheral joints. In addition, there was a statistically significant higher uptake of the tracer in the swollen joints (median uptake ratio compared to background of 3.3 in rheumatoid arthritis and 2.4 in peripheral spondyloarthritis) compared to clinically negative joints (respectively 1.3 and 1.6). CONCLUSIONS: We present a radiolabelling technique for CZP, a Fab'-fragment directed against TNF and currently used as a therapeutic agent in rheumatology. An effective dose of 6.1 mSv (SD 0.9) was estimated. We confirmed the uptake of this new radiopharmaceutical in clinically affected peripheral joints.
引用
- Lambert B, Carron P, D'Asseler Y, et al. 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study. EJNMMI Res. 2016. PMID: 27957720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。